# CLTCL1

Source: https://onco.cc/targets/cltcl1/  
OnCo record `cltcl1` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

CLTCL1 (Clathrin heavy chain 2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Hepatocellular carcinoma, Prostate cancer, Skin cancer and 2 more.

## Summary

Clathrin is the major protein of the polyhedral coat of coated pits and vesicles. Two different adapter protein complexes link the clathrin lattice either to the plasma membrane or to the trans-Golgi network.

Open Targets scores its association with cancer at 0.65 (direct and indirect evidence; datatypes literature 0.31, genetic association 0.08, somatic mutation 0.84). IntOGen calls it a driver in 2 cohorts (0 activating, 2 loss-of-function), covering Hepatocellular Carcinoma, Prostate Adenocarcinoma.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: clathrin heavy chain like 1; Clathrin heavy chain 2; CLH22; CHC22; CLTCL
- Tags: cancer-genes-wave
- Symbol: CLTCL1
- Class: tumor-suppressor
- Biology: Clathrin is the major protein of the polyhedral coat of coated pits and vesicles. Two different adapter protein complexes link the clathrin lattice either to the plasma membrane or to the trans-Golgi network. Location: Cytoplasmic vesicle membrane; Membrane, coated pit (UniProt). Locus 22q11.21 (HGNC).
- Where found: Hepatocellular carcinoma: IntOGen driver in 1 cohort (HCC); Prostate cancer: IntOGen driver in 1 cohort (PRAD); Skin cancer: Open Targets association 0.52 with skin cancer (MONDO_0002898); Lung cancer: Open Targets association 0.51 with lung cancer (MONDO_0008903); Breast cancer: Open Targets association 0.51 with breast cancer (MONDO_0007254)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it a loss-of-function (LoF) driver in 2 cohorts. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:2093: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2093
- UniProt P53675: https://www.uniprot.org/uniprotkb/P53675/entry
- NCBI Gene 8218: https://www.ncbi.nlm.nih.gov/gene/8218
- Ensembl ENSG00000070371: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000070371

## Connected records

- collections: [IntOGen](https://onco.cc/collections/intogen/), [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/), [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/), [Lung cancer (all types)](https://onco.cc/cancers/lung-cancer/), [Prostate cancer](https://onco.cc/cancers/prostate/), [Skin cancer (all types)](https://onco.cc/cancers/skin-cancer/)

---
JSON: https://onco.cc/api/v1/entities/cltcl1.json